 |
|
Radiation therapy can help spare vision in patients with melanoma of the eye
October 19, 2005WINSTON-SALEM - Treating a rare form of eye cancer with radiation therapy can spare patients from significant vision loss, according to new research at Wake Forest University Baptist Medical Center.
The research involved 57 patients with malignant melanoma of the uvea which is the pigmented layer of the eye. The results were reported today at the American Society for Therapeutic Radiology and Oncology (ASTRO) meeting in Denver.
"These are very encouraging results," said Kathryn Greven, M.D., professor of radiation oncology and a study investigator. "The findings in this small series of patients with melanoma treated by Iodine 125 radioactive plaque confirm data obtained in a much larger, earlier study (COMS) that this procedure is effective in controlling the primary tumor, often with good visual outcomes."
Previously, the standard treatment for uveal melanoma was removal of the eye. But, the Collaborative Ocular Melanoma Study (COMS), a multicenter national trial reported in 2001 that radiation was a safe and effective alternative to removing the eye.
The current study involved plaque radiotherapy, which is the most frequently used system for delivering radiation to the eye tumor. With this treatment, a small metal shield containing radioactive seeds is sutured to the outside of the eye over the tumor. The shield is left in place until the required dose of radiation has been delivered, usually for four to five days. Several different type of radiation can be used in the seeds; this study used iodine 125.
The study found that at five years after radiation treatment, 90 percent of patients had their tumors controlled. Before treatment, patients' median visual acuity was visual acuity was 20/30 (which means they could see from 20 feet away what someone with perfect vision can see from 30 feet away). After treatment, media visual acuity was 20/60. In almost half of patients (47 percent) vision was stable after treatment. The researchers found that patients with good pretreatment vision and thinner tumors had better visual outcomes. "Our results show that radiation is an excellent option for certain patients with malignant melanoma of the eye," said Greven.
Uveal malignant melanoma is a rare tumor that occurs in only six per one million people per year in the United States. It is more common in lightly pigmented people and is rarely seen in nonwhite races.
Kathryn Greven in the radiation oncology department and Craig Greven, M.D. a vitreoretinal surgeon in the ophthalmology department have been performing this procedure at Wake Forest University Baptist Medical Center since 1989.
Wake Forest University Baptist Medical Center
Previously, the standard treatment for uveal melanoma was removal of the eye. But, the Collaborative Ocular Melanoma Study (COMS), a multicenter national trial reported in 2001 that radiation was a safe and effective alternative to removing the eye.
The current study involved plaque radiotherapy, which is the most frequently used system for delivering radiation to the eye tumor. With this treatment, a small metal shield containing radioactive seeds is sutured to the outside of the eye over the tumor. The shield is left in place until the required dose of radiation has been delivered, usually for four to five days. Several different type of radiation can be used in the seeds; this study used iodine 125.
The study found that at five years after radiation treatment, 90 percent of patients had their tumors controlled. Before treatment, patients' median visual acuity was visual acuity was 20/30 (which means they could see from 20 feet away what someone with perfect vision can see from 30 feet away). After treatment, media visual acuity was 20/60. In almost half of patients (47 percent) vision was stable after treatment. The researchers found that patients with good pretreatment vision and thinner tumors had better visual outcomes. "Our results show that radiation is an excellent option for certain patients with malignant melanoma of the eye," said Greven.
Uveal malignant melanoma is a rare tumor that occurs in only six per one million people per year in the United States. It is more common in lightly pigmented people and is rarely seen in nonwhite races.
Kathryn Greven in the radiation oncology department and Craig Greven, M.D. a vitreoretinal surgeon in the ophthalmology department have been performing this procedure at Wake Forest University Baptist Medical Center since 1989.
Wake Forest University Baptist Medical Center
Melanoma News and Current Melanoma Events RSSHistory of nonmelanoma skin cancer is associated with increased risk for subsequent malignancies
Individuals with a history of nonmelanoma skin cancer (NMSC) are at increased risk for other cancers, according to a study published in the August 26 online issue of the Journal of the National Cancer Institute.
Researchers discover scent of skin cancer
According to new research from the Monell Center, odors from skin can be used to identify basal cell carcinoma, the most common form of skin cancer. The findings, presented at the 236th meeting of the American Chemical Society, may open doors to development of new methods to detect basal cell carcinoma and other forms of skin cancer.
Fish cancer gene linked to pigment pattern that attracts mates
Though skin cancer is deadly to male fish, it also has one perk: The black melanoma splotches arise from attractive natural markings that lure female mates. A new study published in the Proceedings of the National Academy of Sciences this week shows that the melanoma gene can be conserved in swordtail fish because of its beneficial role in sexual selection.
Prototype test for predicting clinical outcome for melanoma patients
Investigators from the Melbourne Center of the international Ludwig Institute for Cancer Research (LICR) and Pacific Edge Biotchnology Ltd today reported that they have developed a test to predict whether a patient will progress rapidly from Stage III melanoma to metastatic Stage IV cancer and death.
NYU researchers demonstrate activity of mebendazole in metastatic melanoma
Researchers at the NYU Cancer Institute and the Ronald O. Perelman Department of Dermatology have identified mebendazole, a drug used globally to treat parasitic infections, as a novel investigational agent for the treatment of chemotherapy-resistant malignant melanoma.
VCU Massey Cancer Center and VCU Institute of Molecular Medicine Researchers Publish Findings of a New Chemoprevention Gene Therapy That Kills Pancreatic Cancer Cells
Researchers at the Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine have published findings that implicate a new chemoprevention gene therapy (CGT) for preventing and treating pancreatic cancer, one of the most lethal and treatment-resistant forms of cancer.
American Cancer Society study finds high use of complementary methods among cancer survivors
A new study from researchers at the American Cancer Society finds many cancer patients use complementary and alternative methods, most often prayer, relaxation, supplements, meditation, and massage.
Does too much sun cause melanoma?
We are continuously bombarded with messages about the dangers of too much sun and the increased risk of melanoma (the less common and deadliest form of skin cancer), but are these dangers real, or is staying out of the sun causing us more harm than good?
New oral angiogenesis inhibitor offers potential nontoxic therapy for a wide range of cancers
The first oral, broad-spectrum angiogenesis inhibitor, specially formulated through nanotechnology, shows promising anticancer results in mice, report researchers from Children's Hospital Boston.
Inherited melanoma risk: What you do know does help you
When people know the results of genetic tests confirming they have inherited an increased risk of developing melanoma, they follow skin cancer screening recommendations more proactively-much like those who have already been diagnosed with the potentially deadly disease.
More Melanoma News Articles
 | Finding Noel: A Novel by Richard Paul Evans When I wrote my first novel, The Christmas Box, I never imagined it would become an international bestseller. It was a story for my two (then) little girls. But as I wrote, I realized that it was also for my mother -- to ease her pain over losing a child. My mother was my staunchest supporter and my biggest fan. A receptionist at a doctor's office, she would sell my book (sometimes by the case!)... |
 | Understanding Melanoma: What You Need to Know by Perry Robins Newly updated and now in its third edition, this handbook is written for melanoma patients, their families and friends, health professionals, and every person with an interest in the disease. This valuable book, written by two eminent dermatologist, tells all about melanoma from the moment of diagnosis through state- of-the-art treatments. Honest and straightforward, but reassuring in tone.... |
 | 100 Questions & Answers about Melanoma & Other Skin Cancers by Edward F. McClay, Mary-Eileen T. McClay, Jodie Smith This book deals with skin cancer from a doctor's and a patient's... |
 | Histological Diagnosis of Nevi and Melanoma by Guido Massi, Philip E. LeBoit The interpretation of melanocytic tumors represents one of the most important topics and probably the most difficult challenge in the field of dermatopathology. This text and atlas depicts a broad range of the most important or challenging melanocytic lesions. It illustrates in detail melanocytic neoplasms of diagnostic interest encountered in daily practice. It presents a philosophy of... |
 | Saving Your Skin: Prevention, Early Detection, and Treatment of Melanoma and Other Skin Cancers by Dr. Barney Kenet, Patricia Lawler |
 | Pathology of Melanocytic Nevi and Malignant Melanoma Highly acclaimed and considered the leading reference in the field, Pathology of Melanocytic Nevi and Malignant Melanoma has now been fully revised and updated to accomodate rapid advances in the field of melanoma pathology. Drs. Michael Piepkorn and Klaus Busam have now joined Dr. Barnhill, world-renowned expert in dermatology and pathology, to expand the text with new sections on the genetics... |
 | Melanoma: Prevention, Detection, and Treatment; Second Edition (Yale University Press Health & Wellness) by Catherine M. Poole, IV DuPont Guerry The incidence of melanoma has increased by 2000% since 1930, and one person dies each hour from the disease. This cutting-edge guide provides scientifically accurate information patients and their families need in order to understand melanoma and its treatment and to receive vital reassurance. It is also a resource for those who want information about preventing the disease or finding it early... |
 | Color Atlas of Melanocytic Lesions of the Skin This atlas-like presentation covers the various faces of melanocytic skin lesions of cutaneous melanomas and other pigmented skin tumors. It encompasses the classical methods of morphology such as the clinical and dermoscopic examination and dermatopathology as well as the most up-to-date diagnostic approaches such as laser scanning in-vivo microscopy and automated diagnosis. The core of this... |
 | Before I Sleep . . . The Last Days of Dr Tom Dooley by James (editor) Monahan Prince Souphan of Laos arrived at Lambert Field on November 30, 1959, to a proper St. Louis reception led by the deputy mayor and the head of the board of aldermen. The young prince was in town to attend a dinner sponsored by the Junior Chamber of Commerce honoring a thirty-two-year-old native St. Louisan who -- seven years after being nearly expelled from a local medical school -- was returning... |
 | From Melanocytes to Melanoma: The Progression to Malignancy Leading researchers and clinicians join forces to explain how malignant melanoma develops from its benign precursor cell type. The authors focus on the molecular mechanisms involved in melanogenesis, in the malignant transformation of melanocytes, and in the further progression of primary melanomas into invasive and metastatic melanomas. They also review recent advances in our understanding of... |
| © 2008 BrightSurf.com |